Intraperitoneal injection of ADSCs during the disease was expected to lower the inflammatory response, resulting in a decreased incidence of NEC and reduced levels of the inflammatory cytokines IL-1 and IL-6. This evidence concerns the gene IL1B and necrotizing enterocolitis.